clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - clopidogrelhydrochlorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiske midler - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
budesonide/formoterol teva pharma b.v.
teva pharma b.v. - budesonide, formoterol - astma - medicin for obstruktiv sygdomme, - budesonid / formoterol teva pharma b. indikeres kun hos voksne 18 år og ældre. asthmabudesonide/formoterol teva pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.
cegfila (previously pegfilgrastim mundipharma)
mundipharma corporation (ireland) limited - pegfilgrastim - neutropeni - immunostimulants, - reduktion i varigheden af neutropeni og forekomst af febril neutropeni hos voksne patienter behandlet med cytotoksisk kemoterapi for malignitet (med undtagelse af kronisk myeloid leukæmi og myelodysplastisk syndromer).
cyclophosphamid "paranova" 1 g pulver til injektionsv?ske, opl?sning
paranova danmark a/s - cyclophosphamid, vandfrit - pulver til injektionsvæske, opløsning - 1 g
cyclophosphamid carefarm 500 mg pulver til injektionsvæske, opløsning
orifarm a/s - cyclophosphamid, vandfrit - pulver til injektionsvæske, opløsning - 500 mg
bicalutamid "fair-med" 150 mg filmovertrukne tabletter
fair-med healthcare gmbh - bicalutamid - filmovertrukne tabletter - 150 mg
bicalutamid "fair-med" 50 mg filmovertrukne tabletter
fair-med healthcare gmbh - bicalutamid - filmovertrukne tabletter - 50 mg
bicalutamid "paranova" 150 mg filmovertrukne tabletter
paranova danmark a/s - bicalutamid - filmovertrukne tabletter - 150 mg
brinzolamid/timolol "medical valley" 10+5 mg/ml øjendråber, suspension
medical valley invest ab - brinzolamid, timololmaleat - øjendråber, suspension - 10+5 mg/ml
bicalutamid "nordic prime" 150 mg filmovertrukne tabletter
nordic prime aps - bicalutamid - filmovertrukne tabletter - 150 mg